FDA cabergoline label
Defines indication and safety warnings.
Product-specific label.
Original source ↗Loading TrenasCycles…
TrenasCycles
Loading TrenasCycles…
Ancillary / prescription medicine
Dostinex
Cabergoline lowers high prolactin and can help with hormone or fertility problems when prolactin is the cause. It lasts longer than bromocriptine, so treatment is usually less frequent. Nausea and dizziness are common; heart-valve problems and compulsive urges are more serious risks.
Adult hyperprolactinemic disorders. The label requires evaluation for valve disease before treatment; subsequent amounts and continuation are individualized. This is not preventive dosing for a cycle.
Placebo-controlled trials show dose-dependent prolactin suppression. Safety assessment includes orthostatic and valvular considerations.
Nausea, dizziness, orthostatic hypotension, psychiatric/impulse-control effects and possible valvular risk with cumulative exposure.
Health problem link: confirmed hyperprolactinemia. Diagnosis should establish symptoms, repeated prolactin result and underlying cause; monitor per prescriber.
Approved for hyperprolactinemic disorders; not a routine prophylactic add-on to a cycle.
Defines indication and safety warnings.
Product-specific label.
Original source ↗Showed dose-dependent prolactin suppression.
Medical patients under monitoring.
Original source ↗Assessed cumulative exposure and valvular findings.
Observational; not proof of individual risk.
Original source ↗